News AbbVie’s Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology LSP licensee AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology’s 50th Annual Meeting Life Science Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of ABT-806 for the Treatment of Cancer Life Science Pharmaceuticals Enters Into Agreement with Abbott to Develop Antibody 806